藥品異動通知2024.02.02 藥品新增 <27D235> Drospirenone/Estetrol Monohydrate (Alyssa®).自費.錠 新藥介紹 <27D235> Drospirenone/Estetrol Monohydrate (Alyssa®).自費.錠 藥理作用/作用機轉 Combination hormonal contraceptives prevent pregnancy by suppressing ovulation. Drospirenone is a spironolactone analogue with antimineralocorticoid and antiandrogenic activity. Estetrol is a synthetic analogue of a natural estrogen synthesized by the fetal liver and present only during pregnancy. It is not metabolized to estradiol or estriol. 適應症/ 劑量 PO 【Adult】 ●Contraception: 1 tablet QD in the order presented on the blister pack. For patients not currently using a hormonal contraceptive, the first active tablet should be taken on the first day of the menstrual cycle (day 1 start). 【Pediatric】Postmenarche patients ●Contraception: One tablet QD in the order presented on the blister pack. For patients not currently using a hormonal contraceptive, the first active tablet should be taken on the first day of the menstrual cycle (day 1 start). 【Geriatric】Refer to adult dosing. 『Renal Impairment: Adult』 Use is contraindicated 『Hepatic Impairment: Adult』 Use is contraindicated 使用禁忌 Hormonally sensitive malignancy, undiagnosed abnormal uterine bleeding, hepatic adenoma, hepatocellular carcinoma, acute hepatitis, severe (decompensated) cirrhosis, use of ombitasvir/paritaprevir/ritonavir with or without dasabuvir, adrenal insufficiency, kidney impairment. 警告/預防 Bleeding irregularities, cervical cancer, chloasma, cholestasis, hepatic adenomas or carcinomas, hyperkalemia, lipid effects, retinal thrombosis, thromboembolic disorders. 不良反應 【>10%】Gynecological bleeding, mood disorder 【1% to 10%】Acne vulgaris, breast changes, decreased libido, loss of libido, weight gain, dysmenorrhea , depression, headache 【<1%】Thromboembolic complications, hyperkalemia 懷孕用藥分級(FDA) D /避免使用 健保規範 藥品說明: 藥品理由: 其他 粉紅色有效藥錠:15 mg Estetrol Monohydrate (E4) (等同14.2 mg的Estetrol) and 3 mg Drospirenone (DRSP)。 白色無作用藥錠:該藥錠不含有效成分。 應依照鋁箔標示順序使用。 漏服補服方法請見仿單 避免用於抽菸且35歲以上之女性。 偏頭痛狀況若加劇請回診告知醫師。 執行大型手術請提前告知醫師用藥史。 上一篇 下一篇